Mucormycosis and Aspergillosis have been Linked to Covid-19-Related Fungal Infections in India

Mucormycosis and aspergillosis have been recorded in alarmingly high numbers in India in recent decades. Even though fungal infections contribute significantly to human morbidity and mortality, the effect of these diseases on COVID-19 patients is unknown. Mucormycosis and aspergillosis were identified as two post-acute symptoms in COVID-19 patients in this study. Coronavirus 2 of the severe acute respiratory syndrome causes direct damage to the airway epithelium, allowing Mucormycosis and aspergillosis to invade. There were 8,848 infected and 219 dead cases of COVID-19-associated mucormycosis in India as of May 22, 2021. In addition, four Aspergillosis patients have been registered in Bihar, India. In India, a COVID-19-related yellow fungus case was also recorded for the first time. Both mild and moderate-to-severe illness tend to be affected by the syndrome. Despite the urgent need for efficient diagnostic tests, as well as safe and effective new drugs and vaccines, research into the pathophysiology of human fungal infections lags behind that of other